Archived Medical News Stories

<< Back to Main Archives Index

RSSArchived Drug Trial News Stories - October 2010

Date Title Comments Rating
2010-10-30 OptiNose presents sumatriptan Phase II trial results at 2nd European Headache and Migraine Trust International 0 None
2010-10-30 Presidio to present PPI-461 data for HCV infection at AASLD meeting 0 None
2010-10-30 CONCERTA improves handwriting performance in children with ADHD: Study 0 None
2010-10-30 Cipher announces completion of patient enrolment in CIP-ISOTRETINOIN Phase III study for nodular acne 0 None
2010-10-30 Alnylam to present data on RNAi therapeutics for fibrotic diseases at The Liver Meeting 0 None
2010-10-30 Idera presents data on TLR 3 agonist as vaccine adjuvants at Immunological Meeting 0 None
2010-10-30 AVEO to raise $61 million through private placement 0 None
2010-10-30 OHSU to lead next phase of HuCNS-SC trial for NCL in children 0 None
2010-10-29 Cipher completes enrolment in CIP-ISOTRETINOIN Phase III study for severe, nodular acne 0 None
2010-10-29 MAP Pharmaceuticals to present FREEDOM-301 Phase 3 trial data for migraine at EHMTIC Congress 0 None
2010-10-29 GSK and Amicus announce Amigal development and commercialization agreement 0 None
2010-10-29 Shire announces results of Vyvanse Phase 2 signal finding study for Major Depressive Disorder 0 1
2010-10-29 57% of ALK-positive advanced non-small cell lung cancer patients respond to crizotinib: Study 0 None
2010-10-29 ImmuneRegen's Homspera enhances survival of animals vaccinated with experimental melanoma vaccine 0 None
2010-10-29 Coadministration of INTUNIV tablets with stimulant reduces ADHD symptoms 0 None
2010-10-29 Forest, Almirall report topline results from aclidinium bromide comparative Phase III study in COPD 0 None
2010-10-29 StemCells initiates HuCNS-SC second clinical trial for Batten disease in children 0 None
2010-10-29 Geron 2010 third quarter revenue increases from $494,000 to $546,000 0 None
2010-10-29 ImmunoGen first quarter net loss increases to $12.9 million 0 None
2010-10-29 Amira initiates AM152 Phase 1 clinical study for fibrotic diseases 0 None
2010-10-28 Antigenics third quarter net loss decreases from $10.8 million to $5.9 million 0 None
2010-10-28 Pharmasset's PSI-938 phase I monotherapy trial shows positive result for HCV treatment 0 None
2010-10-28 QLT expands QLT091001 Phase 1b LCA study to include patients with Retinitis Pigmentosa 0 4
2010-10-28 Octapharma initiates Human-cl rhFVIII clinical study for severe hemophilia A 0 None
2010-10-28 Pfizer announces publication of crizotinib data for NSCLC patients in New England Journal of Medicine 0 2.5
2010-10-28 Curemark adds two sites in California for CM-AT Phase III clinical trial program 0 None
2010-10-28 Laureate enters agreement with AVEO to produce AV-203 monoclonal antibody against ErbB3 0 None
2010-10-28 Epigenomics presents data on Septin9 biomarker clinical study for colorectal cancer at UEGW 0 3
2010-10-28 Evotec grants Jingxin Pharma rights to develop, market EVT 201 insomnia drug candidate in China 0 None
2010-10-28 ChemoCentryx reports one-year study results of Traficet-EN in Crohn's disease patients 0 None
2010-10-28 EpiCept, FDA reach agreement on regulatory path forward for Ceplene 0 None
2010-10-28 Nymox updates NX-1207 Phase 3 pivotal trials for benign prostatic hyperplasia 0 5
2010-10-28 New oral drug shrinks IMT sarcoma driven by abnormally activated protein 0 None
2010-10-28 BDSI to initiate BEMA Buprenorphine Phase 3 program following positive End-of-Phase 2 meeting with FDA 0 None
2010-10-28 Lotus receives Chinese SFDA approval for R-Bambuterol Hydrochloride Phase I human clinical trials 0 None
2010-10-27 Vical to present preclinical results of HSV-2 vaccine program at Keystone Symposium 0 5
2010-10-27 Intellect obtains initial draft report of OXIGON Phase 1b clinical trial for Alzheimer’s disease 0 None
2010-10-27 MedAvante's centralized ratings to be used in Rexahn's Serdaxin Phase 2a study in MDD patients 0 None
2010-10-27 Decision Resources reduces global sales forecast for tanezumab by $1.2 billion 0 None
2010-10-27 Oramed to present data on oral insulin formulation for Type II diabetes at Annual Meeting in Bethesda 0 None
2010-10-27 Oncolytics presents REO 013 clinical trial data for colorectal cancer at International Symposium in Spain 0 None
2010-10-26 Keryx completes randomization of last patient in Zerenex Phase 3 study for hyperphosphatemia 0 None
2010-10-26 Purdue and Mundipharma assume worldwide development for Infinity's fatty acid amide hydrolase program 0 None
2010-10-26 Agile presents AG200-15 contraceptive patch Phase 2 clinical study results at 66th ASRM 0 None
2010-10-26 TransPharma announces positive results of ViaDerm-hPTH Phase 1 trial for osteoporosis treatment 0 None
2010-10-26 Tengion presents data on Neo-Kidney Augment at Transplantation's Annual Scientific Exchange 0 None
2010-10-26 Phase II data from resminostat SAPHIRE study to be presented at International Hodgkin Lymphoma Symposium 0 None
2010-10-26 Genmab begins Phase III head to head study of ofatumumab vs. rituximab in follicular NHL 0 None
2010-10-26 Celtic, Resolvyx enter option agreement for RX-10045 to treat dry eye syndrome 0 None
2010-10-26 Sanofi-aventis commences teriflunomide Phase III study in RMS patients treated with interferon beta 0 None
2010-10-26 Trius receives patent protection for torezolid phosphate in the U.S. 0 None
2010-10-26 TRACON to present data on TRC105, TRC102 cancer therapies at EORTC-NCI-AACR Symposium 0 None
2010-10-26 Chemoradiotherapy can reduce bladder cancer recurrence 0 None
2010-10-26 ARIAD's oral ridaforolimus improves PFS in patients with metastatic endometrial cancer 0 5
2010-10-26 LigoCyte presents Phase I/II study results of NoV vaccine for gastroenteritis at IDSA Meeting 0 None
2010-10-26 Dual antiplatelet therapy study expanded into Australia and New Zealand 0 None
2010-10-26 Sanofi Pasteur presents Fluzone quadrivalent Phase II trial data for influenza at IDSA Annual Meeting 0 None
2010-10-26 Vertex initiates OPTIMIZE Phase 3b study in patients infected with genotype 1 HCV 0 None
2010-10-25 Repros commences randomization in Androxal Phase II study in T2DM men with low testosterone 0 None
2010-10-25 Inviragen commences Phase 1 clinical trial of DENVax dengue vaccine in Colombia 0 None
2010-10-25 Positive results from Alkermes combination Phase 1 study of ALKS 33 and buprenorphine for cocaine addiction 0 None
2010-10-25 Enrollment complete in ViroPharma's Phase 2 study evaluating subcutaneous delivery of Cinryze 0 None
2010-10-25 Seattle Genetics, Millennium to feature SGN-35 in three poster presentations at ISHL symposium 0 None
2010-10-25 Soligenix reports Phase 2 clinical trial results of orBec for GVHD 0 None
2010-10-25 NovaBay delivers two poster presentations on Aganocide compounds at IDSA Annual Meeting 0 None
2010-10-25 Antigenics expands HSPPC-96 Phase 2 clinical study in glioma 0 None
2010-10-25 Intercell's IC43 Phase II trial against Pseudomonas aeruginosa infections meets primary endpoint 0 None
2010-10-25 Chimerix to present CMX001 data for viral infections at IDSA Annual Meeting 0 None
2010-10-25 Novartis informs Emisphere on First Interpretable Results of two-year Phase III Study 2301 in osteoarthritis 0 None
2010-10-25 Optimer presents two fidaxomicin Phase 3 trials data for CDI infection at IDSA Annual Meeting 0 None
2010-10-25 Pharmaxis announces combined results of Bronchitol Phase III trial for cystic fibrosis 0 None
2010-10-25 Revance presents results of RT001 two Phase 2b clinical trials for lateral canthal lines at Chicago annual meeting 0 None
2010-10-22 Astellas suspends patient enrollment from ACT 5 study of KYNAPID 0 None
2010-10-22 Inspire presents data on denufosol therapy for cystic fibrosis at NACFC conference 0 3
2010-10-22 Talecris announces publication of PROLASTIN-C study results for AAT deficiency in BML journal 0 None
2010-10-22 Gilead announces results from Phase III clinical trial of Cayston, TIS in cystic fibrosis patients 0 5
2010-10-22 TOBI reduces mortality in patients with cystic fibrosis, Pa lung infection 0 None
2010-10-22 AiCuris’ AIC246 inhibitor treats patient with multi-organ HCMV disease 0 None
2010-10-22 Myrexis to present Phase 2 monotherapy study results of Azixa in patients with GBM 0 None
2010-10-22 Novartis releases study results on oral calcitonin for treatment of osteoarthritis: Unigene Laboratories 0 5
2010-10-22 Idera announces IMO-3100 Phase 1 clinical trial results for autoimmune disease 0 None
2010-10-22 Advaxis completes patient recruitment in ADXS11-001 phase II study for cervical dysplasia 0 None
2010-10-21 Astellas suspends enrollment in ACT 5 study of KYNAPID in atrial fibrillation patients 0 None
2010-10-21 Zyvox achieves higher clinical success rate than vancomycin in MRSA nosocomial pneumonia study 0 None
2010-10-21 PolyMedix plans PMX-60056 Phase 2 clinical trial in interventional cardiology 0 None
2010-10-21 BioCryst to present intravenous peramivir data for influenza treatment at IDSA meeting 0 None
2010-10-21 ISCTM to develop solutions for CNS clinical trial methodology 0 None
2010-10-21 OptiNose reports positive results from study of fluticasone delivered by novel device in refractory CRS 0 None
2010-10-21 Intercell and Romark announce IC41-nitazoxanide combination clinical trials for HCV 0 None
2010-10-21 MAP Pharmaceuticals to present nine analyses on LEVADEX for migraine therapy at 2010 EHMTIC congress 0 None
2010-10-21 Quark initiates dosing NAION patients in QPI-1007 Phase I study for ocular neuroprotection 0 None
2010-10-21 Agensys and Seattle Genetics initiate ASG-5ME phase I clinical trial for castration-resistant prostate cancer 0 None
2010-10-21 Aastrom submits SPA for Phase 3 clinical development program in critical limb ischemia to FDA 0 5
2010-10-21 DMC concludes Protege Phase 3 clinical trial for type 1 diabetes lacks efficacy 0 None
2010-10-21 Genzyme third quarter revenue increases to $1.0 billion 0 None
2010-10-21 Alexion announces results of eculizumab two open-label Phase 2 studies for aHUS treatment 0 5
2010-10-21 Genzyme reports results of Clolar combination Phase 3 trial in adult AML 0 None
2010-10-21 IRB approves CEL-SCI’s Multikine Phase III clinical trial for head and neck cancer 0 None
2010-10-20 Arena reports results of APD916 Phase 1 clinical trial for narcolepsy with cataplexy 0 5
2010-10-20 Initiation of INCB28050 Phase IIb trial triggers $19M milestone payment from Eli Lilly to Incyte 0 None
2010-10-20 Rockwell Medical announces design of Phase III development program for Soluble Ferric Pyrophosphate 0 None
2010-10-20 Aradigm reports positive data from DRCFI, ARD-3150 Phase 2b bronchiectasis study 0 None
2010-10-20 European Commission grants Ipsen's OBI-1 orphan drug status for treatment of hemophilia 0 None
2010-10-20 LANL's researcher to implement first human trial of mosaic HIV vaccine candidate 0 None
2010-10-20 Neuralstem updates Phase I human clinical trial of spinal cord stem cells for ALS 0 None
2010-10-20 NIAID announces four new contracts for clinical trials to address problem of antimicrobial resistance 0 None
2010-10-20 MannKind begins MKC1106-MT Phase 2 trial for advanced melanoma 0 None
2010-10-20 Ceregene commences enrollment in CERE-120 Phase 2b study for Parkinson's disease 0 None
2010-10-19 BioMarin announces BMN-111 program for treatment of achondroplasia 0 4
2010-10-19 Rexahn announces publication of 3-aryl-1-isoquinolinamines preclinical data 0 None
2010-10-19 Acorda announces data of GGF2 preclinical studies for focal ischemic stroke 0 None
2010-10-19 Adolor initiates ADL5945 Phase 2 proof-of-concept study for patients with OIC 0 None
2010-10-19 Cytheris initiates ORVACS Phase II clinical trial to study HIV infection 0 None
2010-10-19 Amgen to review study results of ESA in chronic renal failure patients with FDA and CRDAC 0 None
2010-10-19 Positive results from Diamyd Medical's NP2 Enkephalin Phase I trial for chronic pain 0 5
2010-10-19 Novartis announces six-year data of Reclast injection for postmenopausal women with osteoporosis 0 None
2010-10-19 Study investigates effectiveness of potential treatment for Non-alcoholic steatohepatitis 0 None
2010-10-19 New research coalition to design first human trial of mosaic HIV vaccine candidate 0 None
2010-10-19 Transcept announces Intermezzo tablet preliminary data for insomnia 0 None
2010-10-19 Salix presents two Phase 3 pivotal clinical trials data for non-C IBS at ACG Meeting 0 None
2010-10-19 New clinical trial to treat brain cancer launched 0 None
2010-10-19 UCB presents P3, P4 clinical trial data for Crohn's disease at ACG Scientific Meeting 0 None
2010-10-18 Groundbreaking melanoma clinical trial initiated by Patrys 0 None
2010-10-18 BARACLUDE sNDA receives FDA approval for treatment of CHB patients with decompensated liver disease 0 None
2010-10-18 Studies explore impact of upper GI conditions on sleep 0 None
2010-10-18 Sequella to develop SQ109 further with EDCTP, LMU, and TB experts in PanACEA 0 None
2010-10-18 Vertex commences VX-770 and VX-809 combination Phase 2a clinical trial for cystic fibrosis 0 None
2010-10-18 Fluticasone gets rid of eosinophils in the esophagus, but does not improve symptoms 1 3
2010-10-18 Hyperion's HPN-100 granted FDA Fast Track Designation for urea cycle disorders 0 None
2010-10-18 FDA grants fast track designation for Aastrom's CLI cell therapy development program 0 None
2010-10-18 14 global studies on osteoporosis medications FORTEO and EVISTA to be presented at ASBMR 2010 0 None
2010-10-18 BioSante enrolls 2,500th woman in LibiGel Phase III cardiovascular and breast cancer safety study 0 None
2010-10-18 EC grants orphan drug designation to S*BIO's SB1518 for treatment of myelofibrosis 0 None
2010-10-18 Alcon concludes 'proof of concept' clinical trial of NovaBay's Aganocide for viral conjunctivitis treatment 0 None
2010-10-18 Nektar presents data of NKTR-181 mu-opioid analgesic candidate at Pain 2010 Symposium 0 None
2010-10-18 Preliminary Phase 2 data of TZP-102 for diabetic gastroparesis to be presented at ACG annual meeting 0 None
2010-10-18 Cempra to present data on solithromycin, TAKSTA at 48th Annual Meeting in Vancouver 0 5
2010-10-18 Nektar presents NKTR-181 preclinical data at ASA 2010 Annual Meeting 0 None
2010-10-18 PTC announces ataluren Phase 2b efficacy data at International Congress 0 None
2010-10-18 Six-year data of reinforces efficacy and safety of Reclast injection in postmenopausal women with osteoporosis 0 None
2010-10-18 Teva Pharmaceutical announces new data from PreCISe study 0 None
2010-10-15 Neuroprotective properties of laquinimod for RRMS presented at 26th ECTRIMS Congress 0 3
2010-10-15 EC grants orphan medicinal product designation to Allos' pralatrexate for Hodgkin lymphoma 0 None
2010-10-15 NovaDel announces encouraging data from pilot PK study comparing Duromist to Viagra 0 None
2010-10-15 Genentech and Biogen Idec announce positive results from ocrelizumab phase II RRMS study 0 None
2010-10-15 Oseltamivir reduces mortality in influenza A/H5N1 patients 0 None
2010-10-15 Enrollment complete in Inhibitex's FV-100 Phase II clinical trial in shingles patients 0 None
2010-10-15 NovaBay to present two poster presentations at IDSA Annual Meeting 0 None
2010-10-15 Acorda presents new analysis of AMPYRA tablets at ECTRIMS Congress 0 5
2010-10-15 Discovery Labs to present lucinactant Phase 2a clinical study results at NACFC Conference 0 None
2010-10-15 Knopp Neurosciences forms new parent entity 0 5
2010-10-15 Emerging Healthcare anticipates results of FDA-approved human embryonic stem-cell treatment 0 None
2010-10-15 Journal of Clinical Oncology publishes IPI-504 Phase 2 study results 0 None
2010-10-15 Sanofi-aventis announces TEMSO phase III study results for relapsing multiple sclerosis 0 None
2010-10-15 FibroGen announces initiation of FG-3019 phase 2 study for reversing liver fibrosis 0 5
2010-10-15 Genzyme reports five-year patient data from Phase 2 multiple sclerosis trial 0 None
2010-10-14 Omeros receives additional NIDA grant for clinical studies in Addiction program 0 None
2010-10-14 Bayhill to present BHT-3009 Phase 2 clinical trial data at European Committee Congress 0 4
2010-10-14 Sunshine Biopharma to enter Adva-27a Phase I clinical trial for Multi-Drug Resistant breast cancer 0 5
2010-10-14 Acceleron announces ACE-031 Phase 1b study results 0 None
2010-10-14 XenoPort to present XP23829 preclinical data at ECTRIMS meeting 0 None
2010-10-13 Prosensa receives £7.5M milestone payment in GSK2402968 Phase IIa trial for DMD 0 None
2010-10-13 Imprime PGG and cetuximab increase overall response rate in metastatic colorectal cancer 0 None
2010-10-13 Threshold announces TH-302 Phase 1/2 clinical trial interim results 0 None
2010-10-13 JAMA publishes Probuphine Phase 3 clinical trial data 0 None
2010-10-13 Ocular Therapeutix completes Proof of Principle clinical study with moxifloxacin punctum plug 0 None
2010-10-13 Archimedes publishes results from FPNS Phase III clinical study for breakthrough cancer pain 0 None
2010-10-13 Kennedy Krieger Institute launches phase II clinical trial to investigate Revatio for DMD treatment 0 None
2010-10-13 CEL-SCI receives Taiwanese IRB approval for Multikine Phase III trial in head and neck cancer 0 None
2010-10-13 MTN-007 phase trial evaluates vaginal microbicide to prevent rectal transmission of HIV 0 None
2010-10-13 US Oncology enrolls 1,000th patient in Phase I clinical trial 0 None
2010-10-13 HSV1716 clinical trial for childhood cancer receives FDA grant 0 None
2010-10-13 Combination of cetuximab and cisplatin chemotherapy benefits women with triple-negative breast cancer 0 None
2010-10-12 USPTO issues Watson Notice of Allowance for key progesterone patent to treat or prevent preterm birth 0 None
2010-10-12 Alimera to present Iluvien Phase 3 clinical trial data at AAO annual meeting 0 None
2010-10-12 First presentation of anti-HER2 antibody-drug conjugate as first-line therapy for advanced breast cancer 0 None
2010-10-12 Albireo reports positive results from A3309 Phase IIb study in chronic idiopathic constipation 0 None
2010-10-12 Helix completes GLP toxicology study milestone in L-DOS47 development program 0 None
2010-10-12 UCB, Synosia Therapeutics announce new strategic partnership in neurology 0 None
2010-10-12 Halozyme Therapeutics to advance core proprietary programs through key clinical inflection points 0 None
2010-10-12 Erbitux-based therapy helps in early tumor shrinkage, long-term survival in mCRC patients with KRAS wild-type tumors 0 4
2010-10-11 Early cancer drug trials flawed by inconsistencies in prohibited drug lists, study finds 0 None
2010-10-11 Access highlights clinical benefits of MuGard at ESMO conference 0 None
2010-10-11 Merck Serono announces first results from Erbitux BALI-1 study in metastatic triple-negative breast cancer 0 None
2010-10-11 Abbott presents data from 4 briakinumab pivotal studies in psoriasis 0 None
2010-10-11 Boehringer Ingelheim announces results from afatinib clinical trials at 35th ESMO 0 None
2010-10-11 COU-AA-301 Phase 3 study demonstrates improvement in CRPC survival rate 0 None
2010-10-11 ArQule announces SPA with FDA for ARQ 197 Phase 3 trial design for NSCLC 0 None
2010-10-11 Innate Therapeutics initiates MIS416 Phase 2a clinical study in patients with progressive multiple sclerosis 0 4.5
2010-10-11 Genentech initiates GDC-0449 Phase II clinical trial in BCC patients 0 None
2010-10-11 Micromet to initiate MEDI-565 Phase 1 trial in patients with advanced gastrointestinal cancer 0 None
2010-10-11 AVEO presents tivozanib Phase 2 study results at ESMO Congress 0 None
2010-10-11 Geron commences GRNOPC1 hESC-based cell therapy in patients with spinal cord injury 0 None
2010-10-11 ACT Biotech reports positive interim data from Telatinib Phase 2 trial for advanced gastric cancer 0 None
2010-10-11 Eli Lilly presents ALIMTA Phase III trial results at ESMO Annual Meeting 0 None
2010-10-11 ArQule announces ARQ 197 Phase 2 clinical trial results at ESMO annual meeting 0 None
2010-10-11 Allos announces favorable survival data from FOLOTYN Phase 2b study 0 None
2010-10-11 MOH approves BrainStorm's NurOwn stem cell therapy for Phase I/II clinical trial 0 None
2010-10-11 BioSante presents update on LibiGel clinical study at NAMS Annual Meeting 0 None
2010-10-11 OXiGENE announces ZYBRESTAT Phase 2/3 study results at ESMO Congress 0 5
2010-10-11 Afinitor-Sandostatin LAR Depot combination extends median PFS in patients with advanced carcinoid tumors 1 None
2010-10-11 Combination of MET and erlotinib delays lung cancer progression: Study 0 None
2010-10-11 Promising clinical data of ImmunoGen's lorvotuzumab mertansine to be presented at ESMO conference 0 None
2010-10-11 Millennium, Seattle Genetics announce positive top-line results of SGN-35 phase II clinical trial 0 None
2010-10-11 Seattle Genetics reports SGN-75 phase I clinical trial data 0 None
2010-10-11 Auxilium commences dosing in global XIAFLEX phase III program for Peyronie's disease 1 2
2010-10-11 BiondVax commences Multimeric-001 flu vaccine Phase IIa clinical study 0 None
2010-10-11 Phase-II clinical trial of MLN8237 drug shows promising results for treating ovarian cancer 0 None
2010-10-11 First-line treatment with erlotinib drug improves progression-free survival in patients with advanced lung cancer 0 None
2010-10-11 Infinity announces preliminary results of IPI-926 Phase 1 study in patients with solid tumors 0 None
2010-10-11 Anti-HER2 antibody-drug conjugate effective as first-line therapy for advanced breast cancer: Research 0 5
2010-10-08 Phase I study of Shigella dysenteriae bioconjugate vaccine meets primary, secondary endpoints 0 None
2010-10-08 Abiraterone Phase III clinical data to be presented at ESMO meeting 0 5
2010-10-08 Roskamp to initiate RCP-006 clinical trials for Alzheimer's disease 1 5
2010-10-08 Pfizer announces tasocitinib Phase 2 data for plaque psoriasis 0 None
2010-10-08 StemCells provides update on PMD Phase I clinical trial 0 None
2010-10-08 Innovative trial designs may improve efficiency of clinical trials 0 None
2010-10-08 VentiRx announces VTX-1463 trial results for allergic rhinitis treatment 0 None
2010-10-08 Phase 3 study of D-tagatose in Type 2 diabetes shows significant reduction in HbA1c levels 0 None
2010-10-08 Targacept announces top-line results from AZD1446 Phase 2 clinical trial for ADHD 0 None
2010-10-07 Bayer HealthCare, Onyx to present data on Nexavar tablets at ESMO Congress 0 None
2010-10-07 Vivaglobin therapy effective for patients with primary immunodeficiency 0 None
2010-10-07 Myrexis to present MPI-0485520 preclinical data at Annual Scientific Meeting 0 None
2010-10-07 Integra to present multi-center study of peripheral nerve repair at Mexico joint meeting 0 None
2010-10-07 Privigen IVIg therapy effective for primary, secondary immunodeficiencies: Study 0 None
2010-10-07 Hizentra therapy effective for primary immunodeficiency patients 0 None
2010-10-07 Vaccine improves survival of glioblastoma patients in phase II clinical trial: Researchers 0 4
2010-10-07 Ferring Pharmaceuticals announces publication of Phase 3 trials of LYSTEDA tablets for HMB 0 None
2010-10-07 Neoprobe completes pre-NDA assessment for Lymphoseek with FDA 0 None
2010-10-06 Biogen to present late-stage clinical therapies for MS at ECTRIMS Congress 0 None
2010-10-06 Interim data from HyQ Phase III clinical study in primary immune deficiency presented at 26th ESID 0 None
2010-10-06 ISTA Pharmaceuticals announces Phase 1/2 clinical study results of bepotastine besilate nasal spray 0 None
2010-10-06 Synergy reports positive results from plecanatide Phase IIa clinical trial for chronic constipation 0 None
2010-10-06 Adeona completes enrollment in Part 2 CopperProof-2 clinical study 0 None
2010-10-06 Innovacell invests 10 million Euros for clinical development 0 None
2010-10-06 Repinotan blocks respiratory depressant effects of morphine without altering pain-relieving effects 0 None
2010-10-06 Aeterna Zentaris' AEZS-130 demonstrates potential as oral diagnostic test for AGHD 0 None
2010-10-06 Aegerion Pharmaceuticals’ MTP-I Phase III trial published in Atherosclerosis online supplement 0 None
2010-10-06 Rochester General Hospital Research Institute awarded $7M for Prevnar 13 study of ear infections in children 0 None
2010-10-06 IDMC recommends early termination of Phase 3 intramuscular depot aripiprazole trial 0 None
2010-10-06 Lixte, NCI collaborate for clinical evaluation of LB-100 compound 0 None
2010-10-05 Liquidia commences dosing in LIQ-001 Phase 1 trial for seasonal influenza 0 None
2010-10-05 ISTO announces completion of enrollment in NuQu Phase I clinical study for discogenic back pain 0 None
2010-10-05 Archimedes publishes FPNS clinical study results in Pain journal 0 None
2010-10-05 Preclinical data of Enzon's PEG-SN38 in pediatric neuroblastoma published in Clinical Cancer Research 0 None
2010-10-05 ImmunoCellular Therapeutics to present ICT-107 clinical data at World Stem Cell Summit 0 None
2010-10-05 Neuraltus achieves last patient out for NP001, NP002 studies 0 4
2010-10-05 Merck Serono to present Erbitux data at ESMO Congress 0 None
2010-10-05 BioSante to present LibiGel clinical trial update at NAMS Annual Meeting 0 None
2010-10-05 Amgen announces PRIME '203' and '181' Phase 3 trial results 0 None
2010-10-05 Seattle Genetics to present SGN-75 phase I data at ESMO Congress 0 None
2010-10-05 CrystalGenomics to present Phase I MAD study data at Arrowhead Summit 0 5
2010-10-05 Celldex Therapeutics presents initial clinical data on CDX-1401 cancer vaccine candidate at iSBTc meeting 0 None
2010-10-05 Onconova announces agreement with FDA for Estybon- MDS Phase 3 trial 0 None
2010-10-04 Enzo commences clinical trial of Optiquel for chronic non-infectious uveitis 0 None
2010-10-04 Onconova enters agreement with FDA for Estybon Phase 3 trial SPA 0 5
2010-10-04 Merck's boceprevir Phase III studies for HCV to be presented at 61st AASLD 1 None
2010-10-04 Neupro improves quality of life in Parkinson's disease patients 0 None
2010-10-04 AVEO Pharmaceuticals to present tivozanib Phase 2 study results at IKCS Symposium 0 None
2010-10-04 Sanofi-aventis publishes Phase III TROPIC study data in The Lancet article 0 5
2010-10-04 Array BioPharma to present positive interim results of Phase 1 ARRY-380 trial at ASCO Symposium 0 None
2010-10-03 Celsion presents Phase I/II DIGNITY trial data at 2010 Breast Cancer Symposium 0 None
2010-10-03 Bristol-Myers Squibb to present multiple compounds’ data at AASLD annual meeting 0 None
2010-10-03 Isotechnika announces CONFIRM1 clinical trial results at TCT 2010 Symposium 0 None
2010-10-01 Argos' AGS-003 in combination with sunitinib demonstrates favorable PFS for renal cell carcinoma 0 None
2010-10-01 LSUHSC-S receives $3.9M NIDA grant to develop EMB-001 drug for cocaine dependence 0 None
2010-10-01 AcelRx completes ARX-02 End-of-Phase 2 meeting with FDA for cancer breakthrough pain management system 0 None
2010-10-01 Benicar better than Cozaar in reducing blood pressure: Study 0 None
2010-10-01 Intra-Cellular Therapies demonstrates ability of ITI-002 to improve motor and non-motor behaviors in PD 0 None
2010-10-01 FDA grants Emergent Fast Track Designation for AVP-21D9 anthrax monoclonal antibody development program 0 None
2010-10-01 Global phase IV study confirms efficacy of erlotinib in treatment of non-small cell lung cancer 0 None
2010-10-01 Herpevac Trial for Women finds experimental vaccine ineffective in prevention of genital herpes disease 0 5
2010-10-01 Achillion initiates ACH-1625 Phase II dosing for HCV infection 0 None

Total

273 posts
5 comments
51 raters